At Johnson & Johnson, the world’s largest healthcare company, we tirelessly strive to improve access to our innovative medicines, vaccines, devices and diagnostics in all countries, and especially for underserved and vulnerable populations in resource-limited settings. For almost one-third of the global population, medicines and vaccines are not an option.18
Access and pricing: Through active collaboration, we make our medicines readily accessible and affordable for patients and health systems in accordance with the specific reimbursement systems and laws of different countries. Using tools such as equity-based tiered pricing and collaborations with public health organizations,
we strive to help achieve broad and timely access to our medicines in a way that is affordable locally. Our Global Public Health achievements over several years have transformed access to treatments for HIV, TB, NTDs and more (see the Global Public Health Strategy section). As a signatory to the Business for Social Responsibility (BSR) Guiding Principles on Access to Healthcare, we collaborate broadly across our industry to improve access for patients around the world.
Leading the global access ranking: The 2021 Access to Medicine Index (ATMI) was released in January 2021 and we are proud to again rank as one of the top three companies advancing access to medicines in low- and middle-income countries around the world. Our consistent, decade-long recognition of leadership in this independent evaluation is the result of a longstanding, deliberate and focused strategy aimed at solving some of the most difficult global health challenges and advancing equitable access to care for everyone, everywhere.
The ATMI evaluates the world’s 20 largest pharmaceutical companies on their efforts to expand access to medicines. Each new Index raises the bar for the industry as the global health landscape changes and expectations for companies evolve.
6 Johnson & Johnson products are included in the WHO List of Prequalified Medicinal Products:
- Darunavir (ethanolate), Tablet, Film-coated 75mg
- Darunavir (ethanolate), Tablet, Film-coated 150mg
- Darunavir (ethanolate), Tablet, Film-coated 600mg
- Etravirine, Tablet, Film-coated 100mg
- Etravirine, Tablet 25mg
- Mebendazole, Tablets, Chewable 500mg
Pricing transparency in the United States: In early 2021, we published our fifth annual Janssen U.S. Transparency Report, which highlights information related to our R&D investment, approach to pricing and patient support programs. Updates from this year’s report include:
- The average net price decline of Janssen medicines in 2020 was 5.7%.*
- Janssen paid $29.4 billion in rebates, discounts and fees to payers and others in the health system in 2020.*
- Nearly 1.2 million patients were helped with access, affordability and treatment support through Janssen CarePath during COVID-19.**
- 646,000 commercially insured patients reduced their out-of-pocket costs through Janssen CarePath during COVID-19.**
* Figure according to Janssen Internal Financial Accounting.
** Data are an approximate number of patients supported by Janssen CarePath provided by the program administrator.
Intellectual property (IP) management: We believe that flexible IP management is a key element to ensuring sustainable access to medicines, especially in low income and low- to middle-income countries. We work with international funders, local governments and nongovernmental organizations to develop approaches that benefit patients in need while continuing to uphold the value of IP in all parts of the world. For more information, see our Position on Intellectual Property.
Universal Health Coverage (UHC): We are advocates for global UHC and are committed to helping turn the promise of UHC into reality. We believe tailored strategies that align local needs, resources and market conditions must be part of the solution. For more information, see our Position on Universal Health Coverage. In 2020, we achieved our Health for Humanity Goal to drive policy thought leadership and strategic engagements to expand healthcare access and coverage in emerging markets. Several of our Health for Humanity 2025 Goals also address and support progress toward UHC.
In 2020, in support of Universal Health Coverage Day, celebrated each year in December to advocate for equitable health systems worldwide, we drove awareness about our efforts to strengthen health systems and promote public policy that will enable UHC. A key focus for Johnson & Johnson in recent years has been in Kenya, where we maintain a longstanding relationship with the Kenya Ministry of Health through which we continue to support multiple programs, including the Community Health Units for Universal Health Coverage platform, funded by our Johnson & Johnson Foundation, that formally integrates Community Health Volunteers into the health system.
The Community Health Units for Universal Health Coverage platform is geared towards strengthening our community health systems that will empower our communities to demand and participate in quality health systems, and ensure universal access to healthcare, which is equitable, even to the most marginalised populations.
Dr. Maureen Kimani
Head, Division of Community Health, Ministry of Health, Kenya
Throughout the world, we play an active role in dialogue forums and policy initiatives that will move us closer to achieving UHC. In recent years, we have participated in programs in Brazil, Indonesia, Singapore and certain African countries, including Kenya.
Patient engagement: Active collaboration with patients and caregivers helps us understand access needs and inform our development programs. This involves partnering with patients and caregivers to help guide our decision-making throughout the product lifecycle and accelerate patient-inspired innovation. We aim to incorporate patients’ perspectives early in the development of medicines and medical devices, include the patient’s voice in clinical trial protocols and collaborate with patients to develop tailored solutions that empower them in managing their disease.
In 2020, in Europe, we launched a website dedicated to inflammatory bowel disease for patients. This provides a one-stop shop for patients and guides visitors through the patient journey. With this website, we aim to lower the threshold for patients, relatives, caregivers and patient organizations to retrieve relevant, value-added content and services on this disease. Similarly, in several markets, we enhanced our use of digital tools to reach out to patients and gain their perspectives, especially during 2020 when more people were engaging online because of COVID-19 restrictions. In South Korea, we launched a Patient Engagement Program that provides patient support capabilities through various channels including call center, text service and website.
Patient feedback in clinical trials: Now in its fourth year, our Patient Voice in Clinical Trials (PVCT) program continues to incorporate patient perspectives into the design and plans of our pharmaceutical clinical trials. To date, more than 2,500 patients and caregivers from 32 countries have provided feedback in the formal PVCT program. These patient insights have resulted in changes to clinical trials in response to patient feedback, for example:
- Replacing biopsies with imaging;
- Measuring fatigue;
- Reversing the order of assessments;
- Providing transportation; and
- Modifying inclusion or exclusion criteria and informed consent forms.
Patient Engagement Research Councils (PERC): Janssen Scientific Affairs maintains PERCs covering five key disease areas. PERCs are a group of contracted individuals living with a condition of interest that our scientists can work with to quickly gather patient insights over time, and thereby improve how we research, design studies and generate information. In 2020, we added the fifth PERC, covering pulmonary arterial hypertension (PAH), which met to understand attitudes and perceptions toward technology and its use in managing PAH patient health. The insights gathered during the PERC engagement, especially in relation to wearable technology, coupled with data provided through the PAH statistics group, informed the medical affairs study design to expand the inclusion criteria to allow for broader PAH patient trial participation. We also successfully piloted a psoriatic arthritis (PsA) Patient Engagement Day, uniting our employees with PsA PERC members in a virtual dialogue to better understand the patient perspective. In 2020, our PERC communities were especially useful in helping us understand the patient experience during COVID-19 and potential ways in which we could support healthy communities.
Building the next generation of clinical trial design: In our role as the Project Lead of the EU Patient-Centric Clinical Trial Platforms, or EU PEARL, a public-private alliance to develop a common framework for “master protocol” trials to accelerate the development and approval of drugs, we continued our collaboration and engagement. Master protocol trials are used to simultaneously test the effectiveness of multiple medicines on multiple diverse diseases. OCMO
The Johnson & Johnson Office of the Chief Medical Officer
is currently collaborating to develop a Clinical Trial Platform Framework that actively incorporates input from patient representatives for four specific diseases: major depressive disorder, tuberculosis, non-alcoholic steatohepatitis and neurofibromatosis.
Optimizing clinical trials and patient follow-up: Hugo is a novel digital platform that enables the capture and integration of patient real-world data (RWD) from electronic health records, empowering patients to become active partners in health research. During 2020, OCMO continued assessments of the feasibility and value of RWD
capture via the Hugo platform and collaborated to publish joint findings in Nature Digital Medicine, highlighting the potential of the platform to optimize clinical trials by facilitating long-term patient follow-up.